Data as of Jun 17
| -5.88 / -3.51%|
The 25 analysts offering 12-month price forecasts for Novo Nordisk A/S have a median target of 191.10, with a high estimate of 244.01 and a low estimate of 130.08. The median estimate represents a +18.18% increase from the last price of 161.70.
The current consensus among 29 polled investment analysts is to Buy stock in Novo Nordisk A/S. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.